The Safety Profile of Amivantamab and Lazertinib in EGFR-Mutant NSCLC
June 6th 2021Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.
Watch